RUNX1 and acute myeloid leukemia: As discussed earlier, preliminary results combining venetoclax with cytarabine/idarubicin in elderly patients with AML, show deep responses in NPM1 mutated cases (83% MRD negative) and excellent responses in RAS, RUNX1 and IDH1/2 mutated AML cases.